This is a phase 1b study for safety and tolerability of bevacizumab(Avastin)administered into the tumor resection cavity in subjects with Glioblastoma Multiforme (GBM) at first recurrence.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
1
Topical Avastin plus Collagen Sponge placed in surgical cavity after resection of recurrent brain tumor. Dosing range: 0.25 mg/ml - 25 mg/ml.
Brain & Spine Surgeons of New York
White Plains, New York, United States
Maximum Tolerated Dose of bevacizumab (Avastin) following local administration.
Time frame: 4 weeks
Number of Adverse Events
All adverse events will be recorded in the case report form.
Time frame: 12 months
Progression Free Survival
Patients will be followed for survival as well as disease progression for 12 months after treatment.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.